MannKind Corporation (NASDAQ:MNKD) posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.10, RTT News reports. MannKind Corporation had a negative return on equity of 24.93% and a net margin of 71.60%. The firm had revenue of $2.16 million for the quarter, compared to analyst estimates of $2.75 million. During the same quarter last year, the firm posted $0.08 EPS.
Shares of MannKind Corporation (NASDAQ:MNKD) traded up 4.29% during trading on Friday, reaching $1.46. The company had a trading volume of 2,357,104 shares. MannKind Corporation has a 52-week low of $0.41 and a 52-week high of $2.38. The stock has a 50 day moving average of $1.27 and a 200 day moving average of $1.26. The stock has a market capitalization of $152.84 million, a price-to-earnings ratio of 1.10 and a beta of 3.30.
COPYRIGHT VIOLATION NOTICE: “MannKind Corporation (MNKD) Issues Quarterly Earnings Results” was first reported by BNB Daily and is owned by of BNB Daily. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/mannkind-corporation-mnkd-releases-earnings-results-misses-estimates-by-0-10-eps-updated.html.
MNKD has been the topic of a number of research analyst reports. Zacks Investment Research cut MannKind Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. S&P Equity Research cut their target price on MannKind Corporation from $1.04 to $0.83 in a research report on Monday, May 8th. J P Morgan Chase & Co reiterated an “underweight” rating on shares of MannKind Corporation in a research report on Monday, May 22nd. ValuEngine cut MannKind Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, Piper Jaffray Companies set a $1.00 price target on MannKind Corporation and gave the company a “sell” rating in a research report on Thursday, May 11th.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with MarketBeat.com's FREE daily email newsletter.